Salim Syed, a senior Biotech analyst at Mizuho, slashed the price target on Biogen (NASDAQ: BIIB) to $282.00 from ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE